The effects of biscoclaurine alkaloid cepharanthine on mammalian cells: Implications for cancer, shock, and inflammatory diseases

Life Sciences

Volumn 80, Issue 12, 2007, Pages 1073-1079

  Furusawa, Shinobu ^a   Wu, Jianghong ^b  

^a TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Anti inflammatory; Antitumor; Apoptosis; Biscoclaurine alkaloid; Cepharanthine; Multidrug resistance

Indexed keywords

ABC TRANSPORTER; ALKALOID; BUTHIONINE SULFOXIMINE; CEPHARANTHINE; DOXORUBICIN; FLUOROURACIL; GLUTATHIONE; GLYCOPROTEIN P; MITOGUAZONE; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; RECOMBINANT BETA INTERFERON; RECOMBINANT GAMMA INTERFERON; STAPHYLOCOCCUS ENTEROTOXIN A; TAMOXIFEN; VINCRISTINE;

ALOPECIA AREATA; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; IMMUNOMODULATION; INFLAMMATION; LEUKOPENIA; LUNG METASTASIS; MAMMAL CELL; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SECRETORY OTITIS MEDIA; SHOCK; SNAKEBITE; STEPHANIA;

ALKALOIDS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BENZYLISOQUINOLINES; DISEASE MODELS, ANIMAL; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS; SHOCK, SEPTIC; TUMOR CELLS, CULTURED;

HUMAN IMMUNODEFICIENCY VIRUS 1; MAMMALIA; STEPHANIA CEPHALANTHA;

EID: 33846940700     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2006.12.001     Document Type: Review

References (80)

1. Abe T., Koike K., Ohga T., Kubo T., Wada M., Kohno K., Mori T., Hidaka K., and Kuwano M. Chemosensitisation of spontaneous multidrug resistance by a 1,4-dihydropyridine analogue and verapamil in human glioma cell lines overexpressing MRP or MDR1. British Journal of Cancer 72 2 (1995) 418-423
2. Annane D., Bellissant E., and Cavaillon J.M. Septic shock. Lancet 365 9453 (2005) 63-78
3. Aogi K., Nishiyama M., Kim R., Hirabayashi N., Toge T., Mizutani A., Okada K., Sumiyoshi H., Fujiwara Y., Yamakido M., Kusano T., and Andoh T. Overcoming CPT-11 resistance by using a biscoclaurine alkaloid, cepharanthine, to modulate plasma trans-membrane potential. International Journal of Cancer 72 2 (1997) 295-300
4. Asaumi J., Nishikawa K., Matsuoka H., Iwata M., Kawasaki S., Hiraki Y., and Nishijima K. Direct antitumor effect of cepharanthin and combined effect with adriamycin against Ehrlich ascites tumor in mice. Anticancer Research 15 1 (1995) 67-70
5. Azuma M., Aota K., Tamatani T., Motegi K., Yamashita T., Ashida Y., Hayashi Y., and Sato M. Suppression of tumor necrosis factor alpha-induced matrix metalloproteinase 9 production in human salivary gland acinar cells by cepharanthine occurs via down-regulation of nuclear factor kappaB: a possible therapeutic agent for preventing the destruction of the acinar structure in the salivary glands of Sjogren's syndrome patients. Arthritis und Rheum 46 6 (2002) 1585-1594
6. Balendiran G.K., Dabur R., and Fraser D. The role of glutathione in cancer. Cell Biochemistry and Function 22 6 (2004) 343-352
7. Breier A., Barancik M., Sulova Z., and Uhrik B. P-glycoprotein: implications of metabolism of neoplastic cells and cancer therapy. Current Cancer Drug Targets 5 6 (2005) 457-468
8. Cuzzocrea S., Riley D.P., Caputi A.P., and Salvemini D. Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacological Reviews 53 1 (2001) 135-159
9. Davis R.J. The mitogen-activated protein kinase signal transduction pathway. Journal of Biological Chemistry 268 20 (1993) 14553-14556
10. Davis R.J. MAPKs: new JNK expands the group. Trends in Biochemical Sciences 19 11 (1994) 470-473
11. Ebina T., Ishikawa K., and Murata K. Antitumor effect of cepharanthin in the double grafted tumor system. Gan To Kagaku Ryoho 17 6 (1990) 1165-1171
12. Edashige K., Utsumi T., and Utsumi K. Inhibition of 12-O-tetradecanoyl phorbol-13-acetate promoted tumorigenesis by cepharanthine, a biscoclaurine alkaloid, in relation to the inhibitory effect on protein kinase C. Biochemical Pharmacology 41 1 (1991) 71-78
13. Enokida H., Gotanda T., Oku S., Imazono Y., Kubo H., Hanada T., Suzuki S., Inomata K., Kishiye T., Tahara Y., Nishiyama K., and Nakagawa M. Reversal of P-glycoprotein-mediated paclitaxel resistance by new synthetic isoprenoids in human bladder cancer cell line. Japanese Journal of Cancer Research 93 9 (2002) 1037-1046
14. Fidler I.J. Macrophages and metastasis: a biological approach to cancer therapy. Cancer Research 45 10 (1985) 4714-4726
15. Fujihara M., Muroi M., Tanamoto K., Suzuki T., Azuma H., and Ikeda H. Molecular mechanisms of macrophage activation and deactivation by lipopolysaccharide: roles of the receptor complex. Pharmacology and Therapeutics 100 2 (2003) 171-194
16. Fujimura T., Shibata H., Maekawa I., Furusawa S., Kawauchi H., Sasaki K., and Takayanagi Y. Reversal of resistance to doxorubicin with cepharanthine in murine P388 leukemia cells. Japanese Journal of Pharmacology 54 4 (1990) 464-467
17. Furusawa S., Wu J., Fujimura T., Nakano S., Nemoto S., Takayanagi M., Sasaki K., and Takayanagi Y. Cepharanthine inhibits proliferation of cancer cells by inducing apoptosis. Methods and Findings in Experimental and Clinical Pharmacology 20 2 (1998) 87-97
18. Goodwin D.C., Landino L.M., and Marnett L.J. Effects of nitric oxide and nitric oxide-derived species on prostaglandin endoperoxide synthase and prostaglandin biosynthesis. The FASEB Journal 13 10 (1999) 1121-1136
19. Goto M., Zeller W.P., and Hurley R.M. Cepharanthine (biscoclaurine alkaloid) treatment in endotoxic shock of suckling rats. Journal of Pharmacy and Pharmacology 43 8 (1991) 589-591
20. Harada K., Bando T., Yoshida H., and Sato M. Characteristics of antitumour activity of cepharanthin against a human adenosquamous cell carcinoma cell line. Oral Oncology 37 8 (2001) 643-651
21. Kip1. Anticancer Research 23 2B (2003) 1441-1448
22. 2 in rabbit platelets. Biochemical Pharmacology 41 3 (1991) 419-423
23. Hayama M., Inoue R., Akiba S., and Sato T. Inhibitory effect of cepharanthine on fibronectin production in growth factor-stimulated rat mesangial cells. European Journal of Pharmacology 390 1-2 (2000) 37-42
24. Hibasami H., Takaji S., Murata T., and Nakashima K. Cepharanthine potentiates the antitumor effect of methylglyoxal bis (cyclopentylamidinohydrazone) on human leukemia cells. Anticancer Research 11 4 (1991) 1543-1547
25. Ho W.C., Dickson K.M., and Barker P.A. Nuclear factor-κB induced by doxorubicin is deficient in phosphorylation and acetylation and represses nuclear factor-κB-dependent transcription in cancer cells. Cancer Research 65 10 (2005) 4273-4281
26. Hotta T., Tanimura H., Yamaue H., Iwahashi M., Tani M., Tsunoda T., Noguchi K., Mizobata S., and Terasawa H. Synergistic effects of tamoxifen and cepharanthine for circumventing the multidrug resistance. Cancer Letters 107 1 (1996) 117-123
27. Hsueh W., Sun X., Rioja L.N., and Gonzalez-Crussi F. The role the complement system in shock and tissue injury induced by tumour necrosis factor and endotoxin. Immunology 70 3 (1990) 309-314
28. Hunter D.R., Haworth R.A., and Southard J.H. Relationship between configuration, function, and permeability in calcium-treated mitochondria. Journal of Biological Chemistry 251 16 (1976) 5069-5077
29. Ikeda R., Che X.F., Yamaguchi T., Ushiyama M., Zheng C.L., Okumura H., Takeda Y., Shibayama Y., Nakamura K., Jeung H.C., Furukawa T., Sumizawa T., Haraguchi M., Akiyama S., and Yamada K. Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells. Cancer Science 96 6 (2005) 372-376
30. Ito H., Ito H., Amano H., and Noda H. Inhibitory effect of a biscoclaurine alkaloid, cepharanthin, on lung metastasis of Lewis lung carcinoma. Japanese Journal of Pharmacology 56 2 (1991) 195-202
31. Kato T., and Suzumura Y. Potentiation of antitumor activity of vincristine by the biscoclaurine alkaloid cepharanthine. Journal of the National Cancer Institute 79 3 (1987) 527-532
32. Katsui K., Kuroda M., Wang Y., Komatsu M., Himei K., Takemoto M., Akaki S., Asaumi J., Kanazawa S., and Hiraki Y. Cepharanthin enhances adriamycin sensitivity by synergistically accelerating apoptosis for adriamycin-resistant osteosarcoma cell lines, SaOS2-AR and SaOS2 F-AR. International Journal of Oncology 25 11 (2004) 47-56
33. Kaufmann S.H., and Earnshaw W.C. Induction of apoptosis by cancer chemotherapy. Experimental Cell Research 256 1 (2000) 42-49
34. Kimoto T., Suemitsu K., Nakayama H., Komori E., Ohtani M., and Ando S. Therapeutic experience of venomous snakebites by the Japanese viper (Agkistrodon halys blomhoffii) with low dose of antivenin: report of 43 consecutive cases. Nippon Geka Hokan 66 2 (1997) 71-77
35. Kisara S., Hayashi A., Maekawa I., Furusawa S., Takayanagi Y., and Sasaki K. Assay of flow cytometry for the effect of cepharanthine on resistance to doxorubicin. Yakugaku Zasshi 112 11 (1992) 837-845
36. Kisara S., Furusawa S., Murata R., Ogata M., Hikichi N., Takayanagi Y., and Sasaki K. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells. Oncology Research 7 3-4 (1995) 191-200
37. Kisara S., Furusawa S., Takayanagi Y., and Sasaki K. Effect of glutathione depletion by buthionine sulfoximine on doxorubicin toxicity in mice. Research Communications in Molecular Pathology and Pharmacology 89 3 (1995) 401-410
38. Kleinert H., Schwarz P.M., and Forstermann U. Regulation of the expression of inducible nitric oxide synthase. Biological Chemistry 384 10-11 (2003) 1343-1364
39. Kogure K., Goto S., Abe K., Ohiwa C., Akasu M., and Terada H. Potent antiperoxidation activity of the bisbenzylisoquinoline alkaloid cepharanthine: the amine moiety is responsible for its pH-dependent radical scavenge activity. Biochimica et Biophysica Acta 1426 1 (1999) 133-142
40. Kogure K., Tsuchiya K., Abe K., Akasu M., Tamaki T., Fukuzawa K., and Terada H. Direct radical scavenging by the bisbenzylisoquinoline alkaloid cepharanthine. Biochimica et Biophysica Acta 1622 1 (2003) 1-5
41. Kohno H., Inoue H., Seyama Y., Yamashita S., and Akasu M. Mode of the anti-allergic action of cepharanthine on an experimental model of allergic rhinitis. Nippon Yakurigaku Zasshi 90 4 (1987) 205-211
42. Kondo Y., Imai Y., Hojo H., Hashimoto Y., and Nozoe S. Selective inhibition of T-cell-dependent immune responses by bisbenzylisoquinoline alkaloids in vivo. International Journal of Immunopharmacology 14 7 (1992) 1181-1186
43. Kondo Y., Takano F., and Hojo H. Inhibitory effect of bisbenzylisoquinoline alkaloids on nitric oxide production in activated macrophages. Biochemical Pharmacology 46 11 (1993) 1887-1892
44. Kono K., Takahashi J.A., Ueba T., Mori H., Hashimoto N., and Fukumoto M. Effects of combination chemotherapy with biscoclaurine-derived alkaloid (Cepharanthine) and nimustine hydrochloride on malignant glioma cell lines. Journal of Neuro-Oncology 56 2 (2002) 101-108
45. Lee S.H., Lee S.Y., Son D.J., Lee H., Yoo H.S., Song S., Oh K.W., Han D.C., Kwon B.M., and Hong J.T. Inhibitory effect of 2′-hydroxycinnamaldehyde on nitric oxide production through inhibition of NF-κB activation in RAW 264.7 cells. Biochemical Pharmacology 69 5 (2005) 791-799
46. Maruyama H., Kikuchi S., Kawaguchi K., Hasunuma R., Ono M., Ohbu M., and Kumazawa Y. Suppression of lethal toxicity of endotoxin by biscoclaurine alkaloid cepharanthin. Shock 13 2 (2000) 160-165
47. Matsuno T., Orita K., Edashige K., Kobuchi H., Sato E.F., Inouye B., Inoue M., and Utsumi K. Inhibition of active oxygen generation in guinea-pig neutrophils by biscoclaurine alkaloids. Biochemical Pharmacology 39 7 (1990) 1255-1259
48. Morita K., Nakamura M., Nagamachi M., Kishi T., and Miyachi Y. Seventeen cases of alopecia areata: combination of SADBE topical immunotherapy with other therapies. Seventeen cases of alopecia areata: combination of SADBE topical immunotherapy with other therapies. Journal of Dermatology 29 10 (2002) 661-664
49. Mukai M., Che X.F., Furukawa T., Sumizawa T., Aoki S., Ren X.Q., Haraguchi M., Sugimoto Y., Kobayashi M., Takamatsu H., and Akiyama S. Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells. Cancer Science 94 6 (2003) 557-563
50. Murakami K., Okajima K., and Uchiba M. The prevention of lipopolysaccharide-induced pulmonary vascular injury by pretreatment with cepharanthine in rats. American Journal of Respiratory and Critical Care Medicine 161 1 (2000) 57-63
51. Murakami K., Cox R.A., Hawkins H.K., Schmalstieg F.C., McGuire R.W., Jodoin J.M., Traber L.D., and Traber D.L. Cepharanthin, an alkaloid from Stephania cepharantha, inhibits increased pulmonary vascular permeability in an ovine model of sepsis. Shock 20 1 (2003) 46-51
52. Nagano M., Kanno T., Fujita H., Muranaka S., Fujiwara T., and Utsumi K. Cepharanthine, an anti-inflammatory drug, suppresses mitochondrial membrane permeability transition. Physiological Chemistry and Physics and Medical NMR 35 2 (2003) 131-143
53. Nakajima A., Yamamoto Y., Taura K., Hata K., Fukumoto M., Uchinami H., Yonezawa K., and Yamaoka Y. Beneficial effect of cepharanthine on overcoming drug-resistance of hepatocellular carcinoma. International Journal of Oncology 24 3 (2004) 635-645
54. Nakamura K., Tsuchiya S., Sugimoto Y., Sugimura Y., and Yamada Y. Histamine release inhibition activity of bisbenzylisoquinoline alkaloids. Planta Medica 58 6 (1992) 505-508
55. Ohta T., and Morita K. Effect of cepharanthin on radiotherapy induced leucopenia. Rinsho Hoshasen 35 4 (1990) 471-474
56. Okada K., Sakusabe N., Kobayashi A., Hoshi N., and Sato K. Prevention of lung metastasis by intra-tumoral injection of cepharanthin and staphylococcal enterotoxin B in transplantable rat osteosarcoma. Japanese Journal of Cancer Research 90 9 (1999) 928-933
57. Okamoto M., Ono M., and Baba M. Potent inhibition of HIV type 1 replication by an antiinflammatory alkaloid, cepharanthine, in chronically infected monocytic cells. AIDS Research and Human Retroviruses 14 14 (1998) 1239-1245
58. Okamoto M., Ono M., and Baba M. Suppression of cytokine production and neural cell death by the anti-inflammatory alkaloid cepharanthine: a potential agent against HIV-1 encephalopathy. Biochemical Pharmacology 62 6 (2001) 747-753
59. Ono M. Antitumor effect of cepharanthin: mechanism of the antimetastatic effect on Lewis lung carcinoma (3LL). Gan To Kagaku Ryoho 15 2 (1988) 249-255
60. Ono M., Tanaka N., and Orita K. Positive interactions between human interferon and cepharanthin against human cancer cells in vitro and in vivo. Cancer Chemotherapy and Pharmacology 35 1 (1994) 10-16
61. Oyaizu H., Adachi Y., Yasumizu R., Ono M., Ikebukuro K., Fukuhara S., and Ikehara S. Protection of T cells from radiation-induced apoptosis by cepharanthin. International Immunopharmacology 1 12 (2001) 2091-2099
62. Sakaguchi S., Furusawa S., Yokota K., Sasaki K., Takayanagi M., and Takayanagi Y. The enhancing effect of tumour necrosis factor-α on oxidative stress in endotoxemia. Pharmacology and Toxicology 79 5 (1996) 259-265
63. Santos-Silva M.C., Freitas M.S., and Assreuy J. Involvement of NF-κB and glutathione in cytotoxic effects of nitric oxide and taxol on human leukemia cells. Leukemia Research 30 2 (2006) 145-152
64. Sato T., and Ohnishi S.T. In vitro anti-sickling effect on cepharanthine. European Journal of Pharmacology 83 1-2 (1982) 91-95
65. Sato T., Morita I., Fujita H., Ono M., Kimishima A., Tomiyama J., and Murota S. Pharmacological characterization of cepharanthin in chronic idiopathic thrombocytopenic purpura. Platelets 12 3 (2001) 156-162
66. Sawicka M., Kalinowska M., Skierski J., and Lewandowski W. A review of selected anti-tumour therapeutic agents and reasons for multidrug resistance occurrence. Journal of Pharmacy and Pharmacology 56 9 (2004) 1067-1081
67. Shiraishi N., Arima T., Aono K., Inouye B., Morimoto Y., and Utsumi K. Inhibition by biscoclaurine alkaloid of lipid peroxidation in biological membranes. Physiological Chemistry and Physics 12 4 (1980) 299-305
68. Shiraishi N., Akiyama S., Nakagawa M., Kobayashi M., and Kuwano M. Effect of bisbenzylisoquinoline (biscoclaurine) alkaloids on multidrug resistance in KB human cancer cells. Cancer Research 47 9 (1987) 2413-2416
69. Sommers M.S. The cellular basis of septic shock. Critical Care Nursing Clinics of North America 5 1 (2003) 13-25
70. Szewczyk A., and Wojtczak L. Mitochondria as a pharmacological target. Pharmacological Reviews 54 1 (2002) 101-127
71. Terasaka H., Machino M., Saito M., Fujisawa S., Satoh K., Jiang Y., and Sakagami H. Re-evaluation of antitumor activity of cepharanthin. Anticancer Research 22 1A (2002) 165-170
72. Titheradge M.A. Nitric oxide in septic shock. Biochimica et Biophysica Acta 1411 2-3 (1999) 437-455
73. Vercesi A.E., Kowaltowski A.J., Grijalba M.T., Meinicke A.R., and Castilho R.F. The role of reactive oxygen species in mitochondrial permeability transition. Bioscience Reports 17 1 (1997) 43-52
74. Wang Y., Kuroda M., Gao X.S., Akaki S., Asaumi J., Okumura Y., Shibuya K., Kawasaki S., Joja I., Kato H., Himei K., Dendo S., Kanazawa S., and Hiraki Y. Cepharanthine enhances in vitro and in vivo thermosensitivity of a mouse fibrosarcoma, FSa-II, based on increased apoptosis. International Journal of Molecular Medicine 13 3 (2004) 405-411
75. Whitmarsh A.J., and Davis R.J. Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. Journal of Molecular Medecine 74 10 (1996) 589-607
76. Wu J., Suzuki H., Zhou Y.W., Liu W., Yoshihara M., Kato M., Akhand A.A., Hayakawa A., Takeuchi K., Hossain K., Kurosawa M., and Nakashima I. Cepharanthine activates caspases and induces apoptosis in Jurkat and K562 human leukemia cell lines. Journal of Cellular Biochemistry 82 2 (2001) 200-214
77. Wu J., Suzuki H., Akhand A.A., Zhou Y.W., Hossain K., and Nakashima I. Modes of activation of mitogen-activated protein kinases and their roles in cepharanthine-induced apoptosis in human leukemia cells. Cellular Signalling 14 6 (2002) 509-515
78. Yasuda K., Moro M., Akasu M., and Ohnishi A. Pharmacokinetic disposition of cepharanthine following single and multiple intravenous doses in healthy subjects. Japanese Journal of Clinical Pharmacology and Therapeutics 20 4 (1989) 741-749
79. Yasukawa K., Takido M., Takeuchi M., Akasu M., and Nakagawa S. Cepharanthine inhibits two-stage tumor promotion by 12-O-tetradecanoylphorbol 13-acetate and mezerein on skin tumor formation in mice initiated with 7, 12-dimethylbenz[α]anthracene. Journal of Cancer Research and Clinical Oncology 117 5 (1991) 421-424
80. von Knethen A., and Brune B. Cyclooxygenase-2: an essential regulator of NO-mediated apoptosis. The FASEB Journal 11 11 (1997) 887-895